From the publishers of JADPRO

Gastrointestinal Stromal Tumor Resource Center

Advertisement

The immunotherapy in gastrointestinal stromal tumors

Last Updated: Wednesday, August 28, 2024

Treating gastrointestinal stromal tumors (GISTs) with tyrosine kinase inhibitors (TKIs) significantly reduces the risk of recurrence and prolongs survival. This retrospective analysis of relevant literature looked at the effectiveness of immunotherapy in treating GIST, striving to identify the subset of GIST patients who benefit from immunotherapy. 

  

Heliyon
Advertisement
News & Literature Highlights
Advertisement
Advertisement